Nemaura Studies Third Quarter 2018 Monetary Outcomes Nasdaq:NMRD

0
8
Nemaura Reports Third Quarter 2018 Financial Results Nasdaq:NMRD


Loughborough, England – Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com, a medical expertise firm targeted on the event of SugarBEAT® as a non-invasive, inexpensive and versatile Steady Glucose Monitor (CGM) to be used by diabetics and pre-diabetics, yesterday reported monetary outcomes for the third quarter ended December 31, 2018.

Latest Highlights and Accomplishments:

•           Nemaura Signed License and Distribution Settlement for SugarBEAT® Industrial Launch in Qatar

•           Nemaura Efficiently Completes Scientific Research for SugarBEAT® FDA De-Novo 510(okay) Submission

•           Nemaura Raised Circa $2M in Public Providing

•           Nemaura Accomplished Key Phases of Technical File Evaluation for SugarBEAT® CE Mark Approval

•           Nemaura Introduced Enhancements to SugarBEAT® Heat Up Interval  

•           Nemaura Introduced Grant of U.S. Patent for SugarBEAT®

•           Nemaura Introduced Dr. Fred Schaebsdau to Lead Technique and Enterprise Growth

Dr. Faz Chowdhury, CEO of Nemaura Medical, commented, “Over the previous quarter, we’ve bolstered our monetary place to higher help the upcoming industrial launch of SugarBEAT® and submitting of our FDA 510(okay) submission.”

Third Quarter 2018 outcomes:

Analysis and improvement bills elevated to $443,380 for the quarter ended December 2018, a rise of $88,080 for a similar quarter in 2017.

Normal and administrative bills elevated to $489,545 for the quarter ended December 2018, in contrast with $121,053 for a similar quarter in 2017.

The Firm’s complete loss was $964,515 for the quarter ended December 2018, a rise of $534,791 for a similar quarter in 2017.

At December 31, 2018, the Firm’s money  was $5,040,661.

About Nemaura Medical, Inc.:

Nemaura Medical, Inc. (NASDAQ: NMRD), is a medical expertise firm creating SugarBEAT® as a non-invasive, inexpensive and versatile Steady Glucose Monitor (CGM) designed to assist individuals with diabetes and pre-diabetics higher handle their glucose ranges by spending extra time in vary. Insulin customers can adjunctively use SugarBEAT® when calibrated by a finger stick studying. SugarBEAT® consists of a day by day, disposable adhesive skin-patch linked to a small kind issue rechargeable transmitter, linked through Bluetooth to a specifically designed cell software, which shows glucose readings at five-minute intervals all through the day.

For extra info go to:

www.NemauraMedical.com

www.SugarBEAT.com

Cautionary Assertion Concerning Ahead Trying Statements:

The statements on this press launch that aren’t historic info, and should represent forward-looking statements which can be primarily based on present expectations and are topic to dangers and uncertainties that would trigger precise future outcomes to vary materially from these expressed or implied by such statements. These dangers and uncertainties embrace, however aren’t restricted to, dangers associated to regulatory approvals and the success of Nemaura’s ongoing research, together with the protection and efficacy of Nemaura’s SugarBEAT® system, the failure of future improvement and preliminary advertising efforts, Nemaura’s potential to safe further industrial partnering preparations, dangers and uncertainties referring to Nemaura and its companions’ potential to develop, market and promote SugarBEAT®, the supply of considerable further fairness or debt capital to help its analysis, improvement and product commercialization actions, and the success of its analysis, improvement, regulatory approval, advertising and distribution plans and methods, together with these plans and methods associated to SugarBEAT®. These and different dangers and uncertainties are recognized and described in additional element in Nemaura’s filings with the Securities and Change Fee, together with, with out limitation, its Annual Report on Kind 10-Ok for the present 12 months, its Quarterly Studies on Kind 10-Q, and its Present Studies on Kind 8-Ok. Nemaura undertakes no obligation to publicly replace or revise any forward-looking statements.

Contact:

Nemaura Medical Inc.
Bashir Timol
Chief Enterprise Officer
[email protected]



Supply hyperlink

This site uses Akismet to reduce spam. Learn how your comment data is processed.